-
Mashup Score: 60
The PRIMALung EORTC-1901 trial investigates brain MRI ± PCI in all-stages of SCLC, aiming for non-inferior survival, improve cognition in the era of immunotherapy.@finn_corinne
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 30Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis - 13 day(s) ago
Lung cancer is the most frequent cause of cancer-related death worldwide [1], both in men and women. The treatment strategies for lung cancer have rapidly evolved with development of immunotherapies, in particular of the immune checkpoint inhibitors (ICI) for patients with non-small cell lung cancer (NSCLC). The introduction of programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) based ICI therapies has led to significant clinical improvements, representing currently the mainstay of the management of patients with NSCLC [2,3].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Real world analysis of neoadjuvant chemo-immunotherapy @LungCaJournal from Austria. Here, 64% went on to resection, most others then received radiation (96% had some local therapy). At 720d, 79.5% DFS rate overall, 81.5% after resection. https://t.co/m4MxaE4qc1
-
-
Mashup Score: 52
Tumor Erb-B2 receptor tyrosine kinase 2/human epidermal growth factor receptor 2 (ERBB2/HER2) mutations have been reported to occur in 2 %-5% of all cases of non-small cell lung cancer (NSCLC) [1–4]. In-frame insertion mutations in exon 20 (Exon20ins) are the most common type of HER2 mutations in patients with NSCLC, accounting for approximately 90 % of all tumor HER2 mutations in patients with NSCLC [2–5]. Previous studies have mainly described the clinico-genomic and pathological features in patients with NSCLC harboring HER2 Exon20ins [2–4], and the clinico-genomic and pathological features of patients with NSCLC harboring HER2 mutations other than Exon20ins still remain unclear.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Is immunotherapy effective for #HER2 mutant NSCLC? Retrospective look @LungCaJournal from LC-SCRUM at 402 pts with HER2mt NSCLC: 95 had chemo-IO (PFS 8.5m, OS 31.1m) and 173 had chemo alone (PFS 6.3m, OS 23.3m). I suspect targeted therapy here soon. https://t.co/hzAvk52u2d
-
-
Mashup Score: 41Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study - 1 month(s) ago
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard of care for EGFR-mutant non-small cell lung cancer (NSCLC). Initially, first and second-generation EGFR-TKIs proved progression-free survival (PFS) benefits compared to platinum doublets [1]. The PFSs were limited to 10–15 months [1], and acquire resistance to these EGFR-TKIs is inevitable. T790M mutation accounts for over half of such acquired resistant mechanisms [2]. Third-generation EGFR-TKI, osimertinib was developed to overcome T790M-induced resistance.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Phase II ABCD study of afatinib + bevacizumab in #EGFR NSCLC post osimertinib @LungCaJournal (n=28). RR 17.9%, mDOR 9m, mPFS 2.7m, mOS 9.3m. One CR out of 6 pts with C797S and 3 responses in 9 pts with uncommon EGFR mts. https://t.co/q47O4cQpIF
-
-
Mashup Score: 17
Lung cancer is the leading cause of cancer-related mortality, causing around 1.8 million deaths worldwide and accounting for 18 % of all cancer deaths [1]. The most common type of lung cancer is non-small cell lung cancer (NSCLC) comprising around 85 % of all lung cancer cases [2].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Phase Ib study @LungCaJournal of the pan-RAF inhibitor naporafenib (LXH254) with either the ERK1/2 inhibitor rineterkib (LTT462) or the MEK1/2 inhibitor trametinib. In NSCLC, while safe and reductions in DUSP6 mRNA were observed, minimal activity. https://t.co/vdRaiECLpz
-
-
Mashup Score: 19New diagnostic and nonsurgical local treatment modalities for early stage lung cancer - 2 month(s) ago
Exciting advancements have emerged in the field of early-stage lung cancer diagnosis and treatment, leading to the development of new diagnostic and nonsurgical local treatment modalities. These innovative approaches aim to provide accurate and less invasive options for patients.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Our paper online “ New diagnostic and nonsurgical local treatment modalities for early stage lung cancer” A great collaboration with @Mat_Guc and team @LungCaJournal @myESMO @isliquidbiopsy https://t.co/6yTkfrIj7R
-
-
Mashup Score: 63Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology - 2 month(s) ago
MET exon 14 skipping alterations (METex14+) define a distinct and diverse subgroup of non-small cell lung cancer (NSCLC) accounting for 2–4 % of non-squamous NSCLC [1,2]. Epidemiologically, the frequency of METex14+ NSCLC is similar worldwide, occurring in 2.5 % (0.6–5.1 %) in North America compared 2.0 % (0.5–3.3 %) in Europe and 1.7 % (0.5–6.8 %) in Asia [3]. In terms of their pathophysiologic impact, mutations in the MET gene flanking exon 14 lead to METex14+ by producing a MET protein that lacks the Casitas B-Lineage Lymphoma Proto-Oncogene E3 (CBL) protein binding site at Y1003, thereby impairing MET degradation and leading to oncogenic MET signaling [1,3–8].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Comprehensive report on #MET exon 14 mutant NSCLC @LungCaJournal led by Dr. @jennifermarksmd. Over 700 cases included with striking heterogeneity in co-mutations, amplifications, makeup of TME. Also, significant difference in outcomes by histology. https://t.co/mcW896f9L8
-
-
Mashup Score: 44Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study - 2 month(s) ago
MET exon 14 skipping mutations (METex14) are observed in 2 to 4 % of non-small cell lung cancer (NSCLC) patients. They lead to MET receptor stabilization at the membrane and its activation, leading to oncogenic addiction [1]. Preclinical studies have shown that NSCLC patients with METex14 mutations are sensitive to MET inhibitors [2]. METex14 mutations define a distinct subtype of NSCLC patients with specific clinical features, including older age at diagnosis as well as a high proportion of women and never smokers.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
IFCT-2104 CAPMATU study of capmatinib (EAP) in #MET exon 14 mutant NSCLC @LungCaJournal. In real world population (n=146), capmatinib for #METex14 NSCLC had mPFS 4.8m, mOS 10.4m, RR 55.3%. In 1L, mPFS 7.7m. G3-4 edema seen in 8.2% of pts. https://t.co/s64U7brCe1
-
-
Mashup Score: 13
SCLC accounts for approximately 14 % of all lung cancers diagnosed and is characterized by a rapid doubling time and early development of metastatic disease [1]. While SCLC is highly sensitive to initial chemotherapy and radiation therapy, most patients eventually die of recurrent disease [2]. Even with the approval and use of checkpoint inhibitors such as atezolizumab or durvalumab in combination with chemotherapy for newly diagnosed extensive-stage SCLC, more than 80 % of patients experience disease progression by the one-year mark [3,4].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Phase I/II trial of immunomodulator plinabulin plus nivolumab + ipilimumab in #SCLC @LungCaJournal (BTCRC-LUN17-127, n=36). Did not meet target with PFS only 1.6m and OS 5.5m. TRAEs included nausea, vomiting, infusion reaction with 14% with G3+ irAEs. https://t.co/eoFs8oYbsF
-
-
Mashup Score: 36Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma - 3 month(s) ago
Expanding the efficacy of immune checkpoint inhibitors (ICIs) is a major issue for cancer in general and mesothelioma in particular. In pleural mesothelioma, activity with single agent PD-1 inhibitors has been reported [1,2], and the combination of the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab was recently approved by the FDA as a new frontline treatment option [3]. The combination of PD-(L)1 inhibitors and chemotherapy has also been tested in mesothelioma with encouraging activity [4,5], or significant survival improvement [6].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Phase II study of pembrolizumab +/- anetumab ravtansine (mesothelin-targeting ADC) for mesothelin-expressing pleural mesothelioma @LungCaJournal. No sigdifference in RR or PFS with addition of ADC but soluble mesothelin associated with less benefit. https://t.co/Et2aoAoFUH
-
PRIMALung (EORTC 1901) compares brain MRI surveillance to prophylactic cranial irradiation (PCI) in patients with #SCLC. Trials in progress section of @LungCaJournal is a nice addition - allows us to know what to watch for (and nice schema figures). https://t.co/Q9Mh6Dy51v